Australian medical cannabis company AusCann has announced its intention to acquire CannPal Animal Therapeutics. After emerging from a trading halt that began last Friday, AusCann said on Monday it had entered into a scheme implementation deed to acquire 100% of CannPal for around AUD $17.5 million. CannPal is focused on the development of cannabis-based pharmaceutical and nutraceutical products for pets, primarily dogs. AusCann concentrates on the development, production, and distribution of cannabinoid-based medicines for humans.

Sean Hocking, Cannabis Law Report, 11/18/2020 01:24:11

Open article: